Suppr超能文献

改变分割放疗联合同期低剂量或高剂量顺铂治疗头颈部癌症:文献系统评价和荟萃分析。

Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis.

机构信息

Department of Internal Medicine, Hematology, and Oncology, University Hospital Brno, Brno, Czech Republic; School of Medicine, Masaryk University, Brno, Czech Republic.

Scientific Coordination and Biostatistics, Antwerp University Hospital, Edegem, Belgium; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.

出版信息

Oral Oncol. 2018 Jan;76:52-60. doi: 10.1016/j.oraloncology.2017.11.025. Epub 2017 Dec 8.

Abstract

OBJECTIVES

Altered fractionation radiotherapy and concomitant chemoradiotherapy represent commonly used intensification strategies in the management of locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). This meta-analysis compares compliance, safety, and efficacy between two single-agent cisplatin schedules given concurrently with altered fractionation radiotherapy.

METHODS

We systematically searched for prospective trials of patients with LA-SCCHN who received post-operative or definitive altered fractionation concurrent chemoradiotherapy. High-dose cisplatin once every three to four weeks (100 mg/m, 2 doses) was compared with a weekly low-dose protocol (≤50 mg/m, ≥4 doses). The primary outcome was overall survival. The secondary endpoints comprised treatment adherence, acute and late toxicities, and objective response rate.

RESULTS

Twelve studies with 1373 patients treated with definitive chemoradiotherapy were included. Compared to the weekly low-dose cisplatin regimen, the three- to four-weekly high-dose cisplatin regimen improved overall survival (p=.0185), was more compliant with respect to receiving all planned cycles of cisplatin (71% versus 95%, p=.0353), and demonstrated less complications in terms of severe (grade 3-4) acute mucositis and/or stomatitis (75% versus 40%, p=.0202) and constipation (8% versus 1%, p=.0066), toxic deaths (4%, versus 1%, p=.0168), 30-day mortality (8% versus 3%, p=.0154), and severe late subcutaneous fibrosis (21% versus 2%, p<.0001). Overall and complete response rates were similar between both chemotherapy schedules.

CONCLUSION

In chemoradiotherapy incorporating altered fractionation, two cycles of high-dose cisplatin with a three to four week interval are superior to weekly low-dose schedules. Further studies should identify those who might derive the greatest benefit from this intensified approach.

摘要

目的

改变分割放疗和同期放化疗是治疗局部晚期头颈部鳞状细胞癌(LA-SCCHN)的常用强化策略。本荟萃分析比较了两种单药顺铂方案在改变分割放疗中同时应用的依从性、安全性和疗效。

方法

我们系统地检索了接受术后或根治性改变分割同期放化疗的 LA-SCCHN 患者的前瞻性试验。高剂量顺铂每 3-4 周(100mg/m,2 剂)与每周低剂量方案(≤50mg/m,≥4 剂)进行比较。主要结局是总生存。次要终点包括治疗依从性、急性和迟发性毒性以及客观缓解率。

结果

纳入了 12 项涉及 1373 例接受根治性放化疗的患者的研究。与每周低剂量顺铂方案相比,每 3-4 周给予高剂量顺铂方案可改善总生存(p=.0185),顺铂所有计划周期的依从性更高(71%比 95%,p=.0353),且严重(3-4 级)急性黏膜炎和/或口炎(75%比 40%,p=.0202)和便秘(8%比 1%,p=.0066)、毒性死亡(4%比 1%,p=.0168)、30 天死亡率(8%比 3%,p=.0154)和严重迟发性皮下纤维化(21%比 2%,p<.0001)发生率更低。两种化疗方案的总缓解率和完全缓解率相似。

结论

在包含改变分割的放化疗中,每 3-4 周给予 2 个周期的高剂量顺铂优于每周低剂量方案。进一步的研究应确定哪些患者可能从这种强化方法中获益最大。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验